Abstract
Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease. It has one of the strongest cumulative evidence supporting its use in colorectal cancer (CRC) chemoprevention. Epidemiological, clinical, and observational studies have demonstrated that aspirin and non-steroidal antiinflammatory drugs (NSAIDs), including COX-2 inhibitors, can protect against CRC and significantly reduce its incidence. Moreover, prospective randomized controlled trials of colorectal polyp recurrence and in patients with hereditary CRC syndromes have shown that aspirin can produce regression of existing colorectal adenomas and prevent the formation of new polyps. However, the lowest effective doses, treatment duration, target populations, and the effects on survival are not entirely clear. Although not common serious side effects and in particular gastrointestinal and intracerebral hemorrhage do occur, better selection of individuals who might benefit the most from aspirin use must be carefully performed in order to maximize their risk/benefit ratio. In the era of precision medicine, genetic information, blood and/or urinary biomarkers, could potentially help in tailoring chemopreventive therapeutic strategies, based on aspirin use, while limiting adverse toxic effects. The current review will cover the use of aspirin for the prevention of colorectal adenomas and CRC, potential markers for chemoprevention, and patient stratification.
Keywords: Adenomas, aspirin, cardiovascular disease (CVD), colorectal cancer (CRC), non-steroidal anti-inflammatory drugs (NSAIDs), single nucleotide polymorphisms (SNPs).
Current Pharmaceutical Design
Title:Can We Select Patients for Colorectal Cancer Prevention with Aspirin?
Volume: 21 Issue: 35
Author(s): Sarah Kraus, Daniel Sion and Nadir Arber
Affiliation:
Keywords: Adenomas, aspirin, cardiovascular disease (CVD), colorectal cancer (CRC), non-steroidal anti-inflammatory drugs (NSAIDs), single nucleotide polymorphisms (SNPs).
Abstract: Aspirin has been extensively investigated in the context of the prevention of cardiovascular disease. It has one of the strongest cumulative evidence supporting its use in colorectal cancer (CRC) chemoprevention. Epidemiological, clinical, and observational studies have demonstrated that aspirin and non-steroidal antiinflammatory drugs (NSAIDs), including COX-2 inhibitors, can protect against CRC and significantly reduce its incidence. Moreover, prospective randomized controlled trials of colorectal polyp recurrence and in patients with hereditary CRC syndromes have shown that aspirin can produce regression of existing colorectal adenomas and prevent the formation of new polyps. However, the lowest effective doses, treatment duration, target populations, and the effects on survival are not entirely clear. Although not common serious side effects and in particular gastrointestinal and intracerebral hemorrhage do occur, better selection of individuals who might benefit the most from aspirin use must be carefully performed in order to maximize their risk/benefit ratio. In the era of precision medicine, genetic information, blood and/or urinary biomarkers, could potentially help in tailoring chemopreventive therapeutic strategies, based on aspirin use, while limiting adverse toxic effects. The current review will cover the use of aspirin for the prevention of colorectal adenomas and CRC, potential markers for chemoprevention, and patient stratification.
Export Options
About this article
Cite this article as:
Kraus Sarah, Sion Daniel and Arber Nadir, Can We Select Patients for Colorectal Cancer Prevention with Aspirin?, Current Pharmaceutical Design 2015; 21 (35) . https://dx.doi.org/10.2174/1381612821666150915111000
DOI https://dx.doi.org/10.2174/1381612821666150915111000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoclonal Antibody Therapy in Haematological Malignancies
Current Clinical Pharmacology New Synthetic Sulfonamide Chalcone Induced Cell Cycle Arrest and Cell Death in Colorectal Adenocarcinoma Metastatic Cells (SW-620)
Anti-Cancer Agents in Medicinal Chemistry Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets The Production and Role of Gastrin-17 and Gastrin-17-Gly in Gastrointestinal Cancers
Protein & Peptide Letters PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Comprehensive Analysis of Key Proteins Involved in Radioresistance of Prostate Cancer by Integrating Protein-protein Interaction Networks
Current Bioinformatics The Structures and Bioactivities of Fatty Acid Synthase Inhibitors
Current Medicinal Chemistry Benzofuran-Based Estrogen Receptor α Modulators as Anti-Cancer Therapeutics: In Silico and Experimental Studies
Current Medicinal Chemistry Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Role of CCK/Gastrin Receptors in Gastrointestinal/Metabolic Diseases and Results of Human Studies Using Gastrin/CCK Receptor Agonists/Antagonists in these Diseases
Current Topics in Medicinal Chemistry The Glutathione System as an Attractive Therapeutic Target
Drug Design Reviews - Online (Discontinued) Editorial[Hot Topic:Applications of Topological Indices and Complex Networks in Bioinformatics(Guest Editor: Humberto Gonzalez-Diaz)]
Current Bioinformatics Colorectal Cancer – Increased Multidimensional Understanding of the Molecular Genesis
Current Cancer Therapy Reviews Click-Chemistry Reactions in Radiopharmaceutical Chemistry: Fast & Easy Introduction of Radiolabels into Biomolecules for In Vivo Imaging
Current Medicinal Chemistry The Influence of Dietary Components on Early Signs of Atherosclerosis in Apparently Healthy Young-adult Males: An Observational Study of 615 Subjects
Current Vascular Pharmacology Template Dependent Human DNA Polymerases
Current Topics in Medicinal Chemistry An Update on Molecular Research of Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry